Antibody specificity is incredibly important in clinical diagnosis, and OriGene has developed UltraMAB™, the line of ultra specific monoclonal antibodies, to fit the needs of clinicians and researchers. Learn about OriGene’s intensive process for creating an UltraMAB™ against the nuclear protein ERCC1. ERCC1 is used as a biomarker to predict caner patient responsiveness to cisplatin chemotherapy, and OriGene discovered that the existing antibody against ERCC1 was not specific. OriGene used its high-density protein microarray to identify and validate a truly specific anti-ERCC1 UltraMAB™, clone 4F9, which independent researchers have shown to be highly specific and which is now recommended for prognostic use.